Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
780.67
+1.39 (0.18%)
At close: Jul 3, 2025, 1:00 PM
780.00
-0.67 (-0.09%)
After-hours: Jul 3, 2025, 5:00 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $12.73B in the quarter ending March 31, 2025, with 45.17% growth. This brings the company's revenue in the last twelve months to $49.00B, up 36.38% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$49.00B
Revenue Growth
+36.38%
P/S Ratio
14.34
Revenue / Employee
$1,042,621
Employees
47,000
Market Cap
700.84B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Novo Nordisk | 43.92B |
Thermo Fisher Scientific | 42.90B |
LLY News
- 14 hours ago - Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. - Barrons
- 2 days ago - Top 50 High-Quality Dividend Stocks For July 2025 - Seeking Alpha
- 2 days ago - Top 15 High-Growth Dividend Stocks For July 2025 - Seeking Alpha
- 8 days ago - Eli Lilly seen as the stronger bet amid escalating competition with Novo in India - Invezz
- 8 days ago - Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy - Reuters
- 8 days ago - Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate - Seeking Alpha
- 8 days ago - Weight loss and diabetes jabs linked to potentially fatal side effect - Skynews
- 9 days ago - Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground - CNBC